Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis

The Lancet Infectious Diseases

Volumn 18, Issue 3, 2018, Pages 318-327

  Tacconelli, Evelina ^a,b   Carrara, Elena ^a,b   Savoldi, Alessia ^a   Harbarth, Stephan ^c   Mendelson, Marc ^d   Monnet, Dominique L ^e   Pulcini, Céline ^f   Kahlmeter, Gunnar ^g   Kluytmans, Jan ^h,i   Carmeli, Yehuda ^j   Ouellette, Marc ^k   Outterson, Kevin ^l   Patel, Jean ^m   Cavaleri, Marco ⁿ   Cox, Edward M ^o   Houchens, Chris R ^p   Grayson, M Lindsay ^q   Hansen, Paul ^r   Singh, Nalini ^s   Theuretzbacher, Ursula ^t   Magrini, Nicola ^u   Aboderin, Aaron Oladipo ^v   Al Abri, Seif Salem ^v   Awang Jalil, Nordiah ^v   Benzonana, Nur ^v   Bhattacharya, Sanjay ^v   Brink, Adrian John ^v   Burkert, Francesco Robert ^v   Cars, Otto ^v   Cornaglia, Giuseppe ^v   Dyar, Oliver James ^v   Friedrich, Alex W ^v   Gales, Ana C ^v   Gandra, Sumanth ^v   Giske, Christian Georg ^v   Goff, Debra A ^v   Goossens, Herman ^v   Gottlieb, Thomas ^v   Guzman Blanco, Manuel ^v   Hryniewicz, Waleria ^v   Kattula, Deepthi ^v   Jinks, Timothy ^v   Kanj, Souha S ^v   Kerr, Lawrence ^v   Kieny, Marie Paule ^v   Kim, Yang Soo ^v   Kozlov, Roman S ^v   Labarca, Jaime ^v   Laxminarayan, Ramanan ^v   Leder, Karin ^v   Leibovici, Leonard ^v   Levy Hara, Gabriel ^v   Littman, Jasper ^v   Malhotra Kumar, Surbhi ^v   Manchanda, Vikas ^v   Moja, Lorenzo ^v   Ndoye, Babacar ^v   Pan, Angelo ^v   Paterson, David L ^v   Paul, Mical ^v   Qiu, Haibo ^v   Ramon Pardo, Pilar ^v   Rodríguez Baño, Jesús ^v   Sanguinetti, Maurizio ^v   Sengupta, Sharmila ^v   Sharland, Mike ^v   Si Mehand, Massinissa ^v   Silver, Lynn L ^v   Song, Wonkeung ^v   Steinbakk, Martin ^v   Thomsen, Jens ^v   Thwaites, Guy E ^v   van der Meer, Jos WM ^v   Van Kinh, Nguyen ^v   Vega, Silvio ^v   Villegas, Maria Virginia ^v   Wechsler Fördös, Agnes ^v   Wertheim, Heiman Frank Louis ^v   Wesangula, Evelyn ^v   Woodford, Neil ^v   Yilmaz, Fidan O ^v   Zorzet, Anna ^v   more..

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b UNIVERSITY HOSPITAL OF VERONA   (Italy)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^d UNIVERSITY OF CAPE TOWN   (South Africa)

^e EUROPEAN CENTRE FOR DISEASE PREVENTION AND CONTROL ECDC   (Sweden)

^f UNIVERSITY HOSPITAL OF NANCY   (France)

^g CENTRAL HOSPITAL   (Sweden)

^h UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

ⁱ AMPHIA HOSPITAL   (Netherlands)

^j TEL AVIV UNIVERSITY   (Israel)

^k UNIVERSITÉ LAVAL   (Canada)

^l BOSTON UNIVERSITY   (United States)

^m CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

ⁿ EUROPEAN MEDICINES AGENCY   (United Kingdom)

^o CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^p Biomedical Advanced Research and Development Authority   (United States)

^q UNIVERSITY OF MELBOURNE   (Australia)

^r UNIVERSITY OF OTAGO   (New Zealand)

^s GEORGE WASHINGTON UNIVERSITY   (United States)

^t Center For Anti Infective Agents Vienna   (Austria)

^u WORLD HEALTH ORGANIZATION   (Switzerland)

^v NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; NEW DRUG; ANTIINFECTIVE AGENT;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM; BACTERIUM IDENTIFICATION; CAMPYLOBACTER; CARBAPENEM-RESISTANT ENTEROBACTERIACEAE; CEPHALOSPORIN RESISTANCE; CITROBACTER; COMMUNITY ACQUIRED INFECTION; DRUG INDUSTRY; DRUG RESEARCH; ENTEROBACTER; ENTEROCOCCUS FAECIUM; ESCHERICHIA COLI; FUNDING; HAEMOPHILUS INFLUENZAE; HELICOBACTER PYLORI; HUMAN; KLEBSIELLA; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MORGANELLA; MULTIDRUG RESISTANT TUBERCULOSIS; NEISSERIA GONORRHOEAE; NONHUMAN; PRIORITY JOURNAL; PROTEUS; PROVIDENCIA; PSEUDOMONAS AERUGINOSA; SALMONELLA ENTERICA SEROVAR TYPHI; SERRATIA; SHIGELLA; STREPTOCOCCUS PNEUMONIAE; VANCOMYCIN RESISTANT ENTEROCOCCUS; WORLD HEALTH ORGANIZATION; MICROBIOLOGY; TUBERCULOSIS;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; HUMANS; TUBERCULOSIS; WORLD HEALTH ORGANIZATION;

EID: 85038810538     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(17)30753-3     Document Type: Article

References (34)

1. Center for Disease Dynamics, Economics & Policy. State of the world's antibiotics 2015. http://cddep.org/sites/default/files/swa_2015_final.pdf, 2015 (accessed May 17, 2017).
2. WHO. Antimicrobial resistance: global report on surveillance 2014. 2014, World Health Organization, Geneva http://apps.who.int/iris/bitstream/10665/112642/1/9789241564748_eng.pdf?ua=1 (accessed May 17, 2017).
3. WHO. Publications on TB drug resistance. http://www.who.int/tb/publications/drug-resistance/en/ (accessed Dec 18, 2017).
4. WHO. Accelerating progress on HIV, tuberculosis, malaria, hepatitis and neglected tropical diseases. A new agenda for 2016–2030. http://apps.who.int/iris/bitstream/10665/204419/1/9789241510134_eng.pdf?ua=1, 2015 (accessed May 17, 2017).
5. WHO. Global tuberculosis report 2016. 2016, World Health Organization, Geneva http://www.who.int/tb/publications/global_report/en/ (accessed May 17, 2017).
6. Luepke, KH, Suda, KJ, Boucher, H, et al. Past, present, and future of antibacterial economics: increasing bacterial resistance, limited antibiotic pipeline, and societal implications. Pharmacother 37 (2017), 71–84.
7. The Pew Charitable Trusts. Antibiotics currently in clinical development. http://www.pewtrusts.org/∼/media/assets/2017/05/antibiotics-currently-in-clinical-development-03-2017.pdf?la=en, 2017 (accessed June 2, 2017).
8. Jensen, US, Muller, A, Brandt, CT, Frimodt-Moller, N, Hammerum, AM, Monnet, DL, Effect of generics on price and consumption of ciprofloxacin in primary healthcare: the relationship to increasing resistance. J Antimicrob Chemother 65 (2010), 1286–1291.
9. WHO. WHO global strategy for containment of antimicrobial resistance. 2001, World Health Organization, Geneva http://www.who.int/drugresistance/WHO_Global_Strategy_English.pdf (accessed May 17, 2017).
10. The White House. National action plan for combating antibiotic-resistant bacteria. https://obamawhitehouse.archives.gov/sites/default/files/docs/national_action_plan_for_combating_antibotic-resistant_bacteria.pdf, 2015 (accessed Aug 14, 2017).
11. Kostyanev, T, Bonten, MJ, O'Brien, S, et al. The innovative medicines initiative's new drugs for bad bugs programme: European public-private partnerships for the development of new strategies to tackle antibiotic resistance. J Antimicrob Chemother 71 (2016), 290–295.
12. WHO. Global action plan on antimicrobial resistance. 2015, World Health Organization, Geneva.
13. The Global Antibiotic Research and Development Partnership. Developing new antibiotic treatments, promoting responsible use, and ensuring access for all. https://www.dndi.org/diseases-projects/gardp/ (accessed May 17, 2017).
14. The Wellcome Trust. What we do. https://wellcome.ac.uk/what-we-do (accessed May 17, 2017).
15. BARDA. Biomedical Advanced Research and Development Authority. https://www.phe.gov/about/BARDA/Pages/default.aspx (accessed May 17, 2017).
16. CARB-X. Xccelerating global antibacterial innovation. http://www.carb-x.org/ (accessed May 17, 2017).
17. Innovative Medicines Initiative. New drugs for bad bugs. http://www.imi.europa.eu/content/nd4bb (accessed May 17, 2017).
18. OPGA/WHO/FAO/OIE. At UN, global leaders commit to act on antimicrobial resistance. Collective effort to address a challenge to health, food security, and development. http://who.int/mediacentre/news/releases/2016/commitment-antimicrobial-resistance/en/, 2016 (accessed May 17, 2017).
19. Thokala, P, Devlin, N, Marsh, K, et al. Multiple criteria decision analysis for health care decision making. An introduction: report 1 of the ISPOR MCDA emerging good practices task force. Value Health 19 (2016), 1–13.
20. Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States 2013. http://apps.who.int/iris/bitstream/10665/204419/1/9789241510134_eng.pdf?ua=1, 2013 (accessed May 17, 2017).
21. Garner, MJ, Carson, C, Lingohr, EJ, Fazil, A, Edge, VL, Trumble Waddell, J, An assessment of antimicrobial resistant disease threats in Canada. PLoS One, 10, 2015, e0125155.
22. Marsh, K, IJzerman, M, Thokala, P, et al. Multiple criteria decision analysis for health care decision making—emerging good practices: report 2 of the ISPOR MCDA emerging good practices task force. Value Health 19 (2016), 125–137.
23. Moher, D, Liberati, A, Tetzlaff, J, Altman, DG, Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med, 6, 2009, e1000097.
24. Hansen, P, Ombler, F, A new method for scoring additive multi-attribute value models using pairwise rankings of alternatives. Journal of Multi-Criteria Decision Analysis 15 (2008), 87–107.
25. WHO. Prioritization of pathogens to guide discovery, research and development of new antibiotics for drug-resistant bacterial infections including tuberculosis. 2017, World Health Organization, Geneva.
26. WHO. One Health. http://www.who.int/features/qa/one-health/en/, September, 2017 (accessed Dec 18, 2017).
27. Centers for Disease Control and Prevention. National Healthcare Safety Network. https://www.cdc.gov/nhsn/datastat/index.html (accessed May 17, 2017).
28. Nationales Referenzzentrum für Surveillance von nosokomialen Infektionen. KISS (Krankenhaus-Infektions-Surveillance-System) Projektbeschreibung. http://www.nrz-hygiene.de/surveillance/kiss/ (accessed May 17, 2017).
29. Pumart, P, Phodha, T, Thamlikitkul, V, Riewpaiboon, A, Prakongsai, P, Limwattananon, S, Health and economic impacts of antimicrobial resistance in Thailand. J Health Systems Res 6 (2012), 352–360.
30. ECDC/EMEA Joint Working Group. The bacterial challenge: time to react. A call to narrow the gap between multidrug-resistant bacteria in the EU and the development of new antibacterial agents. https://ecdc.europa.eu/sites/portal/files/media/en/publications/Publications/0909_TER_The_Bacterial_Challenge_Time_to_React.pdf, 2009 (accessed May 17, 2017).
31. Laxminarayan, R, Matsoso, P, Pant, S, et al. Access to effective antimicrobials: a worldwide challenge. Lancet 387 (2016), 168–175.
32. de Kraker, ME, Stewardson, AJ, Harbarth, S, Will 10 million people die a year due to antimicrobial resistance by 2050?. PLoS Med, 13, 2016, e1002184.
33. Pulcini, C, Bush, K, Craig, WA, et al. Forgotten antibiotics: an inventory in Europe, the United States, Canada, and Australia. Clin Infect Dis 54 (2012), 268–274.
34. Pulcini, C, Beovic, B, Beraud, G, et al. Ensuring universal access to old antibiotics: a critical but neglected priority. Clin Microbiol Infect, 2017 published online May 15. DOI:10.1016/j.cmi.2017.04.026.